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SUMMARY 
This review examines endpoint reporting in randomized controlled trials (RCTs) of radical 
chemoradiation for the treatment of squamous cell carcinoma of the anus (SCCA). The types, 
frequency, and definitions of clinical primary and secondary endpoints, and patient-reported 
outcome measures (PROMs) reported in the methods and results sections of papers (and 
protocols if available) were examined. Only 6 published RCTs (2877 patients) were 
identified. The primary outcome measures varied across the trials analysed: 2 used disease-
free survival (DFS); 1 Progression-Free Survival; 2 local failure; 1 colostomy-free survival. 
The definition for these terms was not consistent between trials – particularly for treatment 
failure (local, regional, and distant).  Secondary endpoints include overall survival, complete 
clinical response, quality of life, toxicity and compliance. The quality of outcome reporting in 
RCTs of SCCA is inconsistent.  A core outcome set including clinical and PROMs with 
standardised definitions is needed to improve reporting of randomised trials examining 
definitive chemoradiation treatment for SCCA. 
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Introduction 
 
Phase III randomised controlled trials (RCT) are considered the best design to assess the 
efficacy of a particular intervention in clinical medicine - based on clinically meaningful and 
statistically significant impact on patient outcomes. In addition, safety and efficacy are used 
to determine whether a treatment is worth using in clinical practice. Outcome measures such 
as overall survival, disease-free survival, objective response or stable disease, or 
improvements in specific symptoms are balanced against toxicity, loss of function, risk of 
second malignancy or death. In most Phase III cancer trials, overall survival, which is a clear 
and unequivocal event, is considered the benchmark endpoint. Surrogate early endpoints such 
as pathological complete response (pCR) or clinical complete response (cCR) are often useful 
within clinical trials for cancer using chemoradiation (CRT) because they represent a more 
rapidly attained assessment of treatment effects. A recent overview elegantly addresses 
clinical trial endpoints and design in general.1 
Randomised trials of squamous cell carcinoma of the anus (SCCA) have used multiple time-
to-event endpoints with different disease-related and survival events, but a standardised 
definition of the outcome measures is lacking. SCCA has a low rate of distant metastases 
unless recurrence occurs at the primary site. Hence, local control is the primary aim and 
radical chemoradiation (CRT) is the mainstay of treatment, which is associated with 
significant acute and late morbidity.  
In analysing ACT II trial data2, the present authors have discovered many pitfalls in terms of 
the primary and secondary endpoints used in this trial and their definitions when comparing 
results with other trials. For example, The ACT II trial protocol used 3 primary endpoints, the 
complete response rate, recurrence-free survival and acute toxicity. Patients who have had a 
complete local excision (as a result of biopsy or removal of a non-suspicious nodule and 
usually T1NO) were ineligible. However, patients with local excision and involved margins 
were eligible. If disease has been macroscopically resected and there is no evidence of 
residual or nodal disease on imaging, CCR is an inappropriate primary endpoint, and 
recurrence-free survival should be used. In retrospect therefore some endpoints were 
inappropriate for the eligibility.  
Definitions appear to be inconsistent between the different phase III trials. For example the 
definition of local failure may include or exclude disease at sites within the pelvis caused by 
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loco-regional invasion ie inguinal nodes and occasionally includes new separate tumours that 
arise independently in the same area.   
 
The International Rare Cancers Initiative (IRCI) aims to increase international collaboration 
in clinical trials, and has developed a trial for metastatic/relapsed SCCA3. If successful, 
further multicentre international studies will be undertaken but one of the barriers is the 
variably defined outcomes, which require tight standardisation as recommended by both The 
International Conference on Harmonisation (ICH) guidelines4 (ICH) and the CONSORT 
statement4. Endpoint consistency has been previously discussed for squamous cell cancers of 
the head and neck (SCCHN)5 but not for SCCA. Consistent and unambiguous definitions of 
time-to-event endpoints in recurrence has also been highlighted as an issue for more common 
cancers, and the need to avoid changes to the pre-specified primary and secondary outcome 
(endpoint) measures after the trial has started6.  
 
Our aim in this review was to evaluate the standard phase III endpoints, and produce 
recommendations for their definition and use in future trials of SCCA.  
 
LITERATURE SEARCH 
A computerised literature search examined relevant English literature using Pubmed, Medline 
and Cancerlit over the period 1974 to December 2015, supplemented by hand-searching of 
abstracts from recent international meetings. We employed the key words – anal cancer, 
squamous cell carcinoma, local recurrence, survival, concurrent irradiation, chemotherapy, 
radiotherapy (RT), chemoradiation (CRT), combined modality (Online Table 1 includes a full 
list of terms). Studies were eligible if they met the following criteria: patients with SCCA had 
been randomly allocated, or treatment had been prospectively determined. Of the 2139 
records identified through database searching, screening of the titles resulted in the exclusion 
of irrelevant or duplicate publications. Of the 76 abstracts or full-text articles assessed for 
eligibility, 11 publications of 6 randomized relevant trials were found. Only papers published 
in English were reviewed. We read the full text of 148 articles, which seemed likely to offer 
original and relevant information to the scope of this review on the defined endpoints of 
complete clinical response, loco-regional control (LRC), disease-free survival (DFS), 
progression-free survival (PFS) relapse-free survival (RFS), colostomy-free survival (CFS), 
cause-specific (CSS) and overall survival (OS). 
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RESULTS 
Only six phase III randomised controlled trials (RCTs) and updates have been published in 
SCCA over the past 25 years2,8-15. We examined the primary and secondary endpoints and 
their interpretation. Table 1 shows their primary/secondary endpoints and Table 2 how the 
composite disease-related endpoints are variably defined.  
 
1.  Overall Survival (time to death from any cause) and cause-specific survival (time to 
cancer-specific death ) 
Overall survival is a clearly defined endpoint, which is not modified by investigator 
definitions of failure, compliance of patients with long-term follow-up, clinical or 
radiographic assessments, or physician bias. However, the mortality rate is relatively low in 
anal cancer and there are competing risks for death in an elderly population16. To evaluate 
whether a treatment improves survival, a large number of patients or long term follow-up 
would be needed in order to test a realistic effect size. Also, the availability of subsequent 
effective surgical salvage treatment in that location, and the effect of successive treatment 
lines with novel chemotherapy or biological systemic therapy, potentially introduce bias 
because they can prolong survival. In addition, the risk of non-cancer deaths from the 
intervention rises with increasing time.  
 
In ACT I 9 and ACT II 2, only 77% (182/236) and 73% (155/211) deaths respectively were 
due to anal cancer and recent surgical reports suggest abdominoperineal resection for non-
metastatic recurrent or persistent anal cancer can salvage some recurrences, resulting in 5 
years OS around 60%17,18. These factors can substantially dilute the observed treatment effect 
on survival and explain why, despite large differences in local control, in RCT’s comparing 
radiation alone with chemoradiotherapy, initial treatment did not impact on OS9,10,13. 
However significant differences in ACT I were observed using cause-specific survival (CSS) 
as an endpoint (only anal-cancer-related deaths). The disadvantages of this endpoint is the 
potential for misclassification of causes of death and varying practice in the inclusion or 
exclusion of treatment-related death as an event.  
 
2. Other composite time-to-event endpoints 
Other cancer related time-to-event endpoints include a disease-related event such as 
progression or disease recurrence and survival depending on whether all patients have disease 
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which is detectable or not at the time of randomisation.   
Major differences exist in the radiotherapy treatment schedules (planning volumes and 
doses), not only between but also within the individual RCTs, partly because of a reliance on 
early response – either histopathological8 or clinical11,12 to decide the appropriate total 
radiation dose after the first phase of treatment. Also varying compliance with the planned 
treatment as defined by protocolised dose reductions of chemotherapy for toxicity, may 
impact on these results.  
 
2.1. Event-free survival (EFS)   
EFS is not an immediately meaningful term for clinicians unless the event or various events 
of interest are well defined and not excessively complex. The RTOG9811 trial protocol and 
recent phase I/II studies19 define EFS as the time from date of registration to the date of death 
from any cause, first evidence of disease progression, evaluated as non-complete response 
(nCR) at the second evaluation after CR, undergoing colostomy or first evidence of second 
primary cancer, whichever happens first.  
 
2.2. Disease free Survival (DFS) 
DFS serves both as a surrogate endpoint and as an endpoint in itself20. DFS is defined as time 
from randomisation to first event of recurrent disease or death (occasionally 
persistent/progressive disease and/or second primary tumours are counted as events). The 
RTOG 9811 trial11 used DFS as the primary endpoint (which included second malignancies). 
Unless pre-specified, the date of disease recurrence is subject to measurement error and other 
forms of bias, because of differences in the precision and timing of clinical follow-up, and 
radiological and histological assessments between arms. Standardized follow-up protocols 
may therefore be required. 
 
DFS often counts the following as an event: nCR (timed 4-11 weeks following CRT see 
above), radiological local, nodal, pelvic or distant disease following a post CRT CR or death 
from any cause.  However, it is paradoxical to consider this a meaningful endpoint for 
patients who have slow or no response to treatment, but are salvaged by surgery and 
thereafter have no clinical disease. 
 
At randomisation all patients have measurable disease (clinically or radiologically). 
Following chemoradiation the majority become disease-free, but up to 10% will have 
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persistent disease.  This does not fit endpoints such as DFS (usually used following surgery 
when there is a time-point when there is definitely no detectable tumour). Analysis may be 
performed only on patients who are disease-free at a fixed time-point (e.g. 6 months post-
treatment) when the use of DFS is appropriate, but important early information is lost. There 
is both an early and late pattern to loco-regional relapse /failure. There are also patients who 
are never free from disease. Such patients can be considered a treatment failure and we can 
assume that their event occurs at the time of randomisation.   In contrast, for other patients 
there is a point usually 3-9 months following completion of treatment, when we conclude that 
the patient has residual active cancer and surgical salvage is required. This point is when we 
determine that CRT has failed. A positive biopsy may define the endpoint conclusively, but a 
premature positive biopsy may indicate active tumour, which is destined to disappear if the 
tumour is observed for a longer period.  
 
2.3.  Recurrence-free Survival (RFS) 
RFS includes any recurrence (local, regional or distant) and also death due to any cause (both 
anal cancer and non-anal cancer causes of death). In the original ACT II protocol, a primary 
endpoint was recurrence-free survival (defined as first recurrence or death from any cause 
and also date of complete clinical response (CCR).When published we renamed this 
definition to progression-free survival (PFS).   
 
2.4.  Progression free Survival (PFS) 
In ACT II we referred to PFS as the primary endpoint. The original ACT II protocol used the 
term ‘RFS’, at the time of publication this was considered misleading and PFS best suited the 
events included in the original endpoint definition.  The events are captured in a non-
continuous framework, so timing/intervals between the clinical and radiological assessments 
are crucial to the precision of this date. PFS in metastatic disease is not defined by the stable 
persistence of tumour, but by enlargement or the appearance of new lesions. In contrast, in 
SCCA following CRT no observed change to the original primary tumour is eventually 
considered as progression. Hence PFS is ambiguous and a new term is required for patients 
treated with radical CRT with HNSCC, oesophageal cancer, cervix and SCCA. This term 
should accurately capture this event.  
 
PFS can be defined as first clinical detection of disease progression (preferably defined by 
biopsy) (ie, local, regional or distant), recurrence or death from any cause, with censoring of 
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the very few patients who are lost to follow-up or did not experience the event on their date 
last seen alive. This definition of PFS does not capture persistence of primary tumour. PFS 
can therefore be criticised as a primary endpoint because of the potential liability/ subjectivity 
which depends on the frequency and timing of radiographic surveillance. Subsequent lines of 
treatment or salvage surgery can affect OS. So information on subsequent treatment after 
documented progression is essential21. Discussion regarding PFS and its limitations22 is 
beyond the scope of this review.  
 
2.6. Local failure free survival (LFFS) 
In ACT I the primary endpoint in both the protocol and the 1996 report was defined as the 
occurrence of local failure9 which was a composite of local regional failure and the need for 
surgery for treatment-related morbidity, or 6 months after the end of treatment if a pre-
treatment colostomy had not been closed (assessed from 6 weeks after initial treatment). 
Local tumour failure was defined as evidence of persistent local disease, local regrowth or 
local recurrence in the primary tumour after protocol therapy. Patients who never attained 
local control (after chemoradiotherapy) were counted as treatment failures at the first 
assessment post-treatment at 6 weeks. This composite endpoint assumed all patients with 
persistent or recurrent disease would have a colostomy fashioned, which turned out not to be 
the case because 31% (82/265) of patients with local failure were too advanced, too frail or 
otherwise unsuitable for surgery, 8% (20/265) requiring colostomies for treatment morbidity 
and 5% (14/265) unexplained failure to close a pre-treatment colostomy.  By including all 
these events the trial described a population both tumour and colostomy-free, which was a 
useful comparison to surgery as primary therapy, but for contemporary trials separate data on 
disease and colostomy status is required.   
 
Local failure-free-survival seems the most logical endpoint as it includes all relevant events, 
irrespective of surgical salvage and does not have the problems associated with DFS (not all 
patients are disease free at baseline) or PFS (persistent stable disease as an event).  Yet, in the 
RTOG 8704 study patients who had a colostomy, abdominoperineal resection, or exenteration 
for any reason were considered treatment failures on the day of surgery – even if subsequent 
long-term local control was achieved8. Even if salvage surgery remains possible after loco-
regional failure the survival gain may be offset by permanent functional impairment, and a 
decreased quality of life, although many will accept these changes to survive. 
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2.7. Loco-regional failure free Survival (LRFS) 
Regional failure is defined by the RTOG as persistence, regrowth or recurrence of regional 
nodal disease and therefore loco-regional failure can be defined as clinically proven 
(preferably by biopsy) local failure or disease recurrence in pelvic lymph nodes included in 
the original external beam treatment volume, irrespective of any distant failures. Patients with 
persistent disease, who are never disease-free, are considered to be in failure on the day of 
randomisation or if disease disappears and then recurs – on the date of biopsy-proven  or 
convincing imaging evidence of recurrent disease (when available). Salvage surgery for the 
primary site (unless histopathology showed no residual tumour) and death as a result of index 
cancer without a documented site of recurrence or unknown cause are considered LRF.  
 
LRF and metastatic disease should be analyzed separately as the site of first failure. Since 
different doses are mandated for involved nodes and the primary tumour compared to elective 
nodes, it would probably also be important to separate/distinguish local primary failure and 
local regional failure within the treatment fields as separate endpoints, as well as loco-
regional failure outside the treatment fields. The 3-year rate of pelvic loco-regional disease 
related events - based on time-to-event analyses with censoring should be the defining factor. 
 
2.8. Second malignancy 
Second malignancies are common in SCCA. In ACT II 20 patients died of other cancers - in 
total 6 who received mitomycin C (MMC) based CRT and 14 who received cisplatinum 
either as CRT or maintenance2. Some investigators consider the development of SCCA in the 
anorectum after a disease-free interval of 3 to 5 years to be a new primary tumour, therefore 
any “local failure” after 3 to 5 years may be miscategorized and confound the analysis. Other 
studies consider 2nd malignancy as contributing to DFS. Such decision-making should be 
made clear in the protocol, and separated from the key analyses.  
 
2.9. Colostomy-free survival (CFS) 
For patients being both disease, and colostomy-free, is important.  However, only four of the 
six trials reported on this outcome. Both the ACT I and The European Organization for 
Research on Treatment of Cancer (EORTC) 22921 trial showed significant improvement in 
CFS in patients who received chemoradiation compared to radiotherapy10,13. CFS was the 
primary outcome measure of the ACCORD-03 trial, and a secondary endpoint in ACT II and 
RTOG 9811.   
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All trials included colostomy formation as part of salvage surgery after local disease relapse, 
which fails to account for the need for colostomy in the absence of disease occurring either 
post-treatment for excessive faecal discharge/incontinence, or pre-treatment to avoid 
morbidity. Trials do not document whether subsequent reversal is or is not achieved. These 
non-disease colostomy events were included in the CFS analysis in the ACT I and II trials 
and although CFS captures both disease and treatment it is a poorly discriminating 
endpoint23.  This is because the intervention will vary from unit to unit and so is subject to 
inherent selection bias. Pre-treatment colostomy is not part of the randomised allocation, 
some patients refuse to have a stoma for any reason, and there are well-recognised 
geographical and cultural differences in acceptance of a colostomy.  
 
3. Non-time-to-event Endpoints 
 
3.1. Response  
Tumour response is the most commonly used indicator of antitumor activity, and can provide 
an objective assessment - given that cancers rarely shrink spontaneously24. Overall tumour 
response has limitations as a surrogate endpoint for long-term clinical outcomes, but CCR is 
a valid endpoint if there is evidence that this can be sustained for long periods.  
 
In SCCA, sustained CCR after definitive CRT is considered a useful early clinical endpoint, 
because CCR implies destruction of the cancer and possible avoidance of a permanent stoma. 
There is a balance between waiting for a response (a minimum of 4 weeks) versus the need 
for early salvage surgery before the tumour grows and becomes unresectable25. Response to 
CRT has been assessed histopathologically, clinically and radiologically, with a less well-
defined role for endoanal ultrasound and magnetic resonance imaging (MRI)26. 
 
After CRT the interval to best response may be partially dependent on the tumour (size, stage 
or nodal status) or the modality of treatment (radiotherapy or chemoradiation). It is therefore 
clear that standardized serial clinical and imaging assessments are required for follow-up and 
the timing of CCR as an event should be defined eg. CCR 26 weeks from start of treatment25. 
Although standard RECIST criteria27 are applied, the RECIST system was not designed for 
primary tumour assessment, but stipulates assessment at 6-8 weeks and excludes tumours 
under 1 cm. 
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3.2. Adverse events 
The Consolidated Standards of Reporting Trials (CONSORT) guidance offers specific and 
comprehensive guidelines regarding adverse event (AE) reporting in randomized clinical 
trials (RCTs), but adherence to these guidelines appears poor in oncology28. Also, the 
maximum adverse event grade may be less relevant than a progressive worsening of the 
adverse event over time. 
 
3.2.1 Acute toxicity 
Where overall survival is unlikely to be improved by a novel intervention (for example IMRT 
vs standard radiation), acute toxicity may be a suitable primary endpoint29. Different studies 
with varying types and intensities of chemotherapy, with a range of radiotherapy doses and 
schedules would be likely to lead to different toxicity profiles. Acute toxicity and compliance 
have very broad definitions, which include different symptoms and conditions and protocol-
mandated dose reductions. Defining toxicity is also important because the severity of acute 
effects has been correlated with eventual improved outcomes30. 
 
Specific adverse events may be flagged as more important for a particular drug, with the 
causality and duration of the AE episode estimated. The number of patients experiencing 
these adverse events are recorded and distinguished by severity levels and according to 
treatment arm. 
 
Toxicity assessments can be to some extent subjective between patient groups, measured 
using different assessment tools (WHO/NCI/CTC), and provide very different levels of 
compliance depending on the scale of the dose reductions for toxicity recommended. 
Therefore another possible explanation of the heterogeneity demonstrated for toxicity in these 
studies is that they are, indeed, reflecting different results. Furthermore, varying assessment 
periods, 4-8 weeks following completion of treatment, are used.  
 
In the ACT 1 trial the toxicity scale used was simply “mild, moderate and severe” and graded 
subjectively by the investigator9. Although meaningful it is difficult to compare this scale 
with other more modern assessments. The EORTC used the World Health Organisation 
(WHO) 1979 acute morbidity scoring system, but the RTOG-8704 and the RTOG-9811 
assessed chemotherapy toxicity according to the National Cancer Institute (NCI) common 
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toxicity criteria (CTC), and RT toxicity was graded according to RTOG toxicity criteria for 
radiation effects8,11. whereas ACT II used the NCI CTC toxicity scale2. 
 
The use of patient reported outcome measures PROMS is recommended31   because many 
important symptoms are so subjective and often poorly or under-categorised by clinicians32. 
The number and manner of PROMS/QOL measures to be collected should be documented in 
the Patient Information Sheet (PIS) so that patients both understand what might be expected 
and are not worried that they may be questioned too often. 
 
3.2.2. Toxic deaths 
Specific definitions of treatment- or cancer -related mortality in an elderly patient population 
with multiple co-morbidities is problematic. Our experience is that defining death events as 
treatment-related is subjective. It may be better to report cause of death as anal cancer, 
treatment-related (including acute deaths such as neutropenic sepsis or myocardial infarction) 
or as non-cancer deaths. Alternatively, deaths within 90 days of commencing therapy could 
be documented separately.  
 
3.2.3 Late effects 
There is no common language and no standardised and well-defined current system 
developed for both recording and reporting acute and late radiation morbidity. Nor is there an 
accepted time frame - late is usually considered morbidity persistent/existing after 6 or 12 
months, but in some studies is considered only after 5 years. Patients are poor at reporting 
symptoms33 and whilst questionnaires can increase responses, these questions are designed to 
identify pre-morbidity as opposed to radiotherapy-associated effects. The current RTOG late 
effects instrument34 is not sufficiently specific or extensive enough. Hence, appropriate 
PROMS are in development (see QOL). 
.  
3.2.4 Tolerability 
Secondary tolerability endpoints could include: 
 (1) Dose intensity achieved (mg/m2/week): the total dose per body surface area divided by 
the duration of drug treatment (the number of weeks between start and finish of 
chemotherapy) 
 (2) The relative dose intensity (%): ie the ratio of the dose intensity achieved compared to 
the planned dose intensity 
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 (3) The relative treatment duration: the ratio of the duration of treatment observed in the trial 
to the planned duration of treatment. 
The reasons for reductions, delays, omissions should be documented to indicate whether due 
to toxicity or other cause. 
 
3.3. Compliance 
Compliance refers to the degree or extent of conformity to the trial recommendations with 
respect to timing, dosage, and frequency of intended treatment. Compliance should be 
distinguished from continuance of the treatment for the prescribed duration35. 
 
Reporting compliance is essential for the interpretation of results and to inform the impact of 
the treatment when applied in a real world setting. Definitions vary. Without data on 
compliance reproducibility of trial results may not be possible. For example in the RTOG 98-
11 the definition of radiotherapy compliance was ‘per protocol and an acceptable minimal 
variation’ in radiation dose thereby categorising patients with less than total dose as 
compliers. Compliance in ACT II was defined as patients receiving full dose only.  Clear 
descriptions of median radiation dose received and overall treatment time (OTT) with 
interquartile ranges are required. A simple composite classification of the adequacy of radical 
chemoradiation using three grades based on the actual drug doses received, the dose intensity 
and duration in days of any planned or unintended break in treatment may suffice. 
 
Compliance to concurrent chemotherapy is also problematic as the chemotherapy dose will 
be compromised to ensure maximum radiotherapy dose if toxicity occurs. The second course 
of chemotherapy is crucial to maintain efficacy36. A conservative trial design allowing 50% 
dose-reductions for subsequent chemotherapy courses if grade 3 or above specific toxicities 
occur will have a lower dose intensity than less permissive protocols.  A more useful 
summary might be to report both total dose and dose intensity curves37  
 
3.4. Patient Reported Outcomes (PROMS)  
Only two trials captured data on Quality of Life (QoL) due to the absence of available 
validated questionnaires specific to SCCA at the time of trial design. Using generic 
Rotterdam Symptom Checklist and Hospital Anxiety and Depression Scales 
chemoradiotherapy appeared to improve QOL compared to radiotherapy alone, but this was 
probably due to better disease control38. Some used the EORTC QLQ-C30 and Anal 
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Sphincter Conservative Treatment Questionnaire short-term QOL in SCCA during treatment 
and shortly after to document QOL39. There are known adverse effects of pelvic radiotherapy 
on continence and quality of life40. A mixed methods approach to PROMs for patients treated 
for SCCA identified gaps in the currently available questionnaires, and indicate that the 
EORTC-QLQ questionnaire is the most comprehensive in terms of symptom items41. We 
therefore recommend including long-term reports of continence and/or QoL using PROMS in 
future trials.  
 
DISCUSSION 
An important limitation of this analysis is that it is based on only 6 randomized trials with 
different entry criteria and different treatments. As the efficacy of chemoradiotherapy 
improves in SCCA, and  higher RT doses are integrated with more sophisticated irradiation 
techniques such as intensity modulated radiotherapy (IMRT), we may observe similar 
findings to head and neck cancer, where loco-regional control and overall survival is 
decoupled, because distant events after treatment are more common. 
 
A systematic review of 125 RCTs found clear definitions even of the survival endpoint were 
lacking in almost half these papers42. Much effort has been expended on adjuvant endpoints 
following surgery and for metastatic disease, but there has been less focus on endpoints 
following radical treatment of loco-regional pelvic disease with chemoradiation. Neither the 
EORTC radiotherapy group 43 nor more recent aspirations designing phase III trials 
specifically addressed such endpoints44. 
 
The choice of the most appropriate and unambiguous outcome measures is a vital component 
of trials as promoted by the (CONSORT) statement6. The utility of cross-trial comparisons 
and meta-analyses remain limited45. Positive results can also sometimes represent a chance 
finding, or factors within an underpowered trial provide a heterogeneous patient population 
which confound the results46.   
 
At baseline all patients prior to CRT have disease and the majority achieve a complete 
response, others despite initial response are never free from disease and either remain in this 
state, or have no detectable disease following salvage surgery.  Current outcomes such as 
DFS and PFS can be  difficult to apply in this situation as they are most clearly used when 
patients either have undetectable disease or measurable disease at the point of origin and are 
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therefore all at risk of recurrence or progression. Also the tumour may initially respond, but 
the nadir may not be defined and the actual date of progression is never likely to be 
accurately defined but overestimated by the timing of the next scan or doctor visit. 
 
Current trials in (SCCHN) use PFS and its components (LRF and DM), which are often 
reported instead of protocol-specified disease-free-survival to facilitate comparison with 
published meta-analyses47.  
 
Usually 3-9 months following completion of treatment, if tumour is still present, we conclude 
that the patient has residual active cancer and chemoradiation has failed. Either radiologically 
the tumour enlarges or a steady persistence of disease at this arbitrary time-point becomes 
defined as progression. There is necessarily not a clear distinct line between disease and no 
disease, but it represents a dynamic process.  
It is also well recognised that secondary endpoints are often defined and assessed less 
rigorously48.  The need to develop optimal primary and secondary endpoints for clinical 
trials, will become increasingly important as the trials get more complex. Improvements in 
trial design need to be accompanied by improvements in available endpoints and patients and 
investigators will need to work together to achieve this49. 
 
CONCLUSION 
The objectivity, reliability, and validity of the current endpoints in clinical trials are variable. 
Time-to-event (TTE) endpoints other than OS share little uniformity across RCTs in SCCA. 
Different trials use different procedures to consider a patient as having an event which is not 
consistent with other studies. Rigorous definitions and consistent terminology are mandatory 
for future studies. The validity and feasibility of these endpoints for future international trials 
has already been discussed in IRCI meetings and we hope to work towards a consensus 
document.  
 
We recommend consistency in reporting acute and late toxicity and compliance, and support 
the DATECAN project50 for consensus-based recommendations. In rare cancers, 
unanimously agreed definitions are essential, because large long-term studies are few and 
difficult to perform. Journals in particular should agree to accept only standard definitions for 
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survival endpoints. Hence investigators, statisticians, reviewers, and editors should all take 
responsibility for the precision of trial endpoints.  
 
The ideal objective for gauging success in future SCCA phase III trials should be anal 
dysfunction-free survival. An internationally agreed definition should form the primary 
endpoint. We recommend the following secondary endpoints: OS and CSS as well as 
information on deaths not due to anal cancer. The late effects of radiotherapy captured by 
PROMS with long-term follow-up are essential. We also recommend the use of CFS and RFS 
- which includes any recurrence (local or regional, or distant) and also death due to any cause. 
Long-term follow-up for overall survival is still required in case unexpected adverse effects 
of treatment are not captured by this earlier endpoint. Yet, with the increasing development of 
more effective immunological treatments for metastatic disease, RFS may be less relevant 
and uncoupled from OS. Since most recurrences occur within the first 3 years, a minimum of 
3 years monitoring and follow-up is mandatory for the required number of events to be 
captured. 
 
Future randomised trials in SCCA should document the median/mean radiation dose 
received, and the compliance to chemotherapy during each week of treatment (as a 
percentage of the intended dose), the total dose of radiation achieved, the OTT, the precise 
site of recurrence in relation to radiotherapy fields.  
 
Finally, we recommend that methodological research should address the validation of 
surrogate end-points, (such as local control/complete clinical response at 6 months).  
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Table 1. Primary and secondary endpoints in Randomised trials 
 
Trial Primary Endpoint Secondary Endpoints 
ACT 16,16 Local treatment failure (composite of 
local failure and need for colostomy 
for toxicity) 
Overall survival  
EORTC7 Local failure   Event-free survival  
RTOG 87048 Disease‐free survival. Overall survival  
Colostomy-free survival,  
Time to colostomy 
Loco-regional control, 
Incidence of negative post induction biopsy 
Incidence of positive salvage biopsy,  
Toxicity rates) 
RTOG 98114 Disease‐free survival. Overall Survival 
Cumulative incidence of Colostomy 
Cumulative Incidence of Local Regional 
Failure and Distant Metastases; 
Toxicity 
Hazard ratios for tumor markers P53 
overexpression, human papilloma virus 
status and enzyme marker HAP1. 
ACCORD 035 Colostomy-free survival Overall survival 
Cancer-specific survival  
Local control 
ACT II6 (2 separate endpoints for 2x2 
factorial design) Recurrence-free 
survival  
Complete response (complete 
disappearance of clinically and 
radiologically overt disease) 
and acute toxicity: grade 3/4 t up to 4 
weeks post-chemo for MMC/CisP 
comparison  
Overall survival 
Cancer-specific survival  
Colostomy rate 
In-field recurrence rate  
 
Table 2:  Definition of composite disease-related endpoints used in Anal Cancer Trials  
 
Trial Endpoint Loco-regional 
disease^ 
Pelvic 
disease^^ 
Distant 
metastases 
Death New tumour Colostomy 
^^^ 
ACT I1 Local Treatment Failure       
ACT II6 Progression-Free Survival*       
EORTC7 Event-Free Survival       
ACCORD 035 Event-Free Survival       
RTOG 
87048 
Disease-Free Survival       
RTOG 98114 Disease-Free Survival        
*definition for RFS defined in protocol used but renamed PFS  
^ locoregional disease includes original site and associated lymph nodes 
^^ pelvic disease includes other pelvic organs and lymph nodes within the pelvis 
^^^ colostomy for treatment morbidity in absence of disease 
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Table 3:  Time-to-event endpoints used in Anal Cancer Trials  
 
 ACT19,13 EORTC10 RTOG8  
8704 
RTOG     
981111.14,15 
ACCORD 0312 ACT II2 
2Disease-related time to event endpoints 
Local recurrence  LRFa     
Local recurrence, distant metastases, new tumour +death   DFSb DFS   
Local recurrence, distant metastases, +death      PFSd 
Local recurrence, new tumour + death  EFSc     
Local recurrence, distant metastases, colostomy rate  + death      EFS  
Local recurrence + colostomy due to recurrence/ complications LRF      
Survival endpoints       
All deaths OSe     OS 
Anal cancer and treatment related deaths CSSf     CSS 
Colostomy related time to event endpoints 
Colostomy any cause or death CFSg   CISh CFS CRi (CFS) 
aLocoregional failure; bDisease-free survival; cEvent-free survival; dProgression-free survival (PFS reported although RFS in protocol);  
eOverall survival; fCause-specific survival  
gColostomy-free survival10; hCumulative incidence of colostomy; iColostomy rate 
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Table 4 pros and cons of currently used endpoints 
Endpoint Utility Pros Cons 
Overall 
Survival 
Gold standard endpoint in randomised trials  Easy to define, precise 
universally accepted 
available via registries 
Less robust as patient benefit if older 
population and if surgery can salvage >50% 
Cause-Specific 
Survival 
Cause-specific survival focuses on the impact of the 
cancer on survival. Competing events are treated as 
censoring events, and death from causes unrelated to 
carcinoma is considered lost to follow-up as of date of 
death.  Cause-specific survival analysis minimises the 
impact of age, co-morbidity and other risk factors on 
survival rates. 
Easy to define, widely 
accepted. Useful in a cancer 
which affects elderly patients, 
and has effective surgical 
salvage.  
Reliable information on the cause of death is 
not always available. Death certificates are 
often inaccurately reported. 
Disease Free 
Survival 
Often used post-surgery when no detectable disease 
present at randomisation. Difficult to use in CRT trials 
as proportion never disease free  So ?censored 
Earlier endpoint than OS 
Requires fewer numbers and 
shorter follow-up 
Not validated as surrogate for survival in anal 
cancer.  Definitions vary between trials. Can 
depend on frequency of imaging 
Relapse/  
recurrence 
Free Survival 
Used as primary endpoint when no detectable disease 
present at trial entry.  Difficult to use in CRT trials as 
many never disease free So  censored 
Earlier endpoint than OS 
Requires fewer numbers and 
shorter follow-up 
Subject to assessment bias 
Can depend on frequency of imaging 
Progression 
Free Survival 
Often used in metastatic setting when all patients have 
disease at randomisation. Used as primary endpoint in 
trials 
Objective/quantitative 
Not affected by salvage 
surgery with APER or 
subsequent treatment 
Stable disease not necessarily of clinical 
benefit 
Subject to assessment bias 
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Colostomy-
Free Survival 
Used as primary endpoint in trials Easy to define Initial colostomy can be reversed but often not 
reversed 
Colostomy can be formed both for recurrence 
and late effects 
Complete 
clinical 
response 
Often used as a surrogate endpoint especially in phase 
II and phase III trials 
Assessed early (6 months) 
smaller studies possible 
 
Imperfect surrogate endpoint                               
Needs to be sustained for clinical benefit          
Not direct measure of clinical benefit Time 
dependent. Prone to immortal time bias 
 
Online Table 1.  Complete list of search terms applied 
Area Terms 
Anal Cancer 
Anus neoplasm (MeSH term) 
Anal neoplasm 
Anal cancer 
Anus cancer 
Anal carcinoma 
Anus carcinoma (no hits) 
Anal canal cancer 
Anal canal carcinoma 
Anal tumour 
Anus tumour (no hits) 
Anal intraepithelial neoplasia 
Anal canal intraepithelial neoplasia 
Anal squamous intraepithelial lesions 
Anal squamous cell carcinoma 
Anal cloacogenic carcinoma (no hits) 
Cloacogenic carcinoma of the anal canal 
 
Treatments 
Radiochemotherapy 
Stoma  
Chemoradiotherapy 
Radiochemotherapy 
Chemoradiation 
Chemotherapy 
Radiotherapy 
Combined modality therapy 
Antineoplastic chemotherapy 
Antineoplastic agents 
Colostomy 
Surgical stoma (Exp Stoma and stoma bag) 
 
Health-related quality of life 
Quality of Life 
QOL 
Health related quality of life 
HRQOL 
Subjective health status 
Patient reported outcome 
Patient based outcome 
Patient reported outcome measure 
PROM 
Self report 
Side effect 
Toxicity 
Adverse effect 
Adverse event 
Safety 
Complication 
Dysfunction 
Disturbance 
Disorder 
Impairment 
Complaint 
Symptom 
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Table 2: Showing important compliance to RT parameters 
 
Mean Dose of RT received  Median  Range  
% of patients receiving 90-110% of total 
dose recommended 
Median  Range  
Number of days RT omitted Median  Range Reasons 
Number of days RT dose reduced  Median  Range Reasons 
Overall treatment time (OTT) in days Median  Range Reasons 
 
Table 3: Showing important compliance to chemotherapy parameters 
 
Mean Dose of chemotherapy received  Median  Range  
% of patients receiving 90-110% of total 
dose recommended 
Median  Range  
Number of days chemotherapy omitted Median  Range Reasons 
Number of days chemotherapy  dose 
reduced  
Median  Range Reasons 
If delay in administration - Overall 
treatment time (OTT) in days 
Median  Range Reasons 
 
 
